Similarly, the value of GLP-1 RA therapies in reducing adverse outcomes has been shown with liraglutide in those with DM with and without CVD [28], as well as subcutaneously administered semaglutide [12], but not oral semaglutide [29]. Here, GLP1R is linked to diabetes mellitus.